{"id":52239,"date":"2025-12-30T13:59:40","date_gmt":"2025-12-30T05:59:40","guid":{"rendered":"https:\/\/flcube.com\/?p=52239"},"modified":"2025-12-30T13:59:41","modified_gmt":"2025-12-30T05:59:41","slug":"haihe-biopharmas-risovalisib-enters-china-spark-project-for-pediatric-pik3ca-disorders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52239","title":{"rendered":"Haihe Biopharma&#8217;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders"},"content":{"rendered":"\n<p><strong>Haihe Biopharma Co., Ltd.<\/strong> announced that <strong>risovalisib mesylate (CYH33)<\/strong>, a highly potent and selective <strong>PI3K\u03b1 inhibitor<\/strong>, has been included in the <strong>Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project)<\/strong> by China\u2019s <strong>Center for Drug Evaluation (CDE)<\/strong>. The designation covers <strong>PIK3CA\u2011Related Overgrowth Spectrum (PROS)<\/strong> and <strong>PIK3CA\u2011Related Vascular Malformations (PRVM)<\/strong> in pediatric patients requiring systemic therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Risovalisib mesylate (CYH33)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Haihe Biopharma (full global IP rights)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>SPARK Project (Pediatric Anti\u2011Tumor Drug Development Pilot)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>PROS and PRVM with severe clinical manifestations<\/td><\/tr><tr><td><strong>Regulator<\/strong><\/td><td>CDE, NMPA (China)<\/td><\/tr><tr><td><strong>Designation Date<\/strong><\/td><td>25\u202fDec\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-intellectual-property\">Drug Profile &amp; Intellectual Property<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Highly selective PI3K\u03b1 inhibitor<\/strong> with novel chemical structure<\/li>\n\n\n\n<li><strong>Intellectual Property<\/strong>: <strong>Full global IP rights<\/strong> held by Haihe Biopharma; no licensing obligations outside Japan<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: <strong>First\u2011in\u2011class<\/strong> oral small\u2011molecule targeting the PIK3CA pathway for rare pediatric overgrowth disorders<\/li>\n\n\n\n<li><strong>Pediatric Focus<\/strong>: SPARK Project designation provides <strong>priority review, waived clinical trial fees, and dedicated CDE guidance<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-status\">Clinical Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Geography<\/th><th>Indication<\/th><th>Status<\/th><th>Partner<\/th><\/tr><\/thead><tbody><tr><td><strong>Japan<\/strong><\/td><td>PIK3CA\u2011mutant ovarian clear cell carcinoma (OCCC)<\/td><td><strong>NDA submitted (Aug\u202f2025)<\/strong><\/td><td><strong>Taiho Pharmaceutical<\/strong> (exclusive Japan rights, Oct\u202f2025)<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>PROS\/PRVM (pediatric)<\/td><td><strong>SPARK Project inclusion (Dec\u202f2025)<\/strong><\/td><td>Haihe Biopharma (retains rights)<\/td><\/tr><tr><td><strong>Global<\/strong><\/td><td>Solid tumors (PIK3CA\u2011mutant)<\/td><td>Phase\u202fII ongoing<\/td><td>Haihe Biopharma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-market-context\">Disease Market Context<\/h2>\n\n\n\n<p><strong>PROS\/PRVM Prevalence<\/strong>: Rare congenital disorders affecting <strong>1\u20112 per 100,000<\/strong> births in China, translating to an estimated <strong>2,000\u20114,000 pediatric patients<\/strong>. Current standard of care is <strong>symptomatic management<\/strong> (surgery, compression therapy) with <strong>no approved systemic therapy<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Diagnosed pediatric PROS\/PRVM patients (China)<\/strong><\/td><td>2,500<\/td><td>3,200<\/td><\/tr><tr><td><strong>Risovalisib\u2011eligible (severe, systemic)<\/strong><\/td><td>1,000<\/td><td>1,400<\/td><\/tr><tr><td><strong>Annual therapy cost (\u00a5, pre\u2011reimbursement)<\/strong><\/td><td>\u00a5250,000<\/td><td>\u00a5200,000<\/td><\/tr><tr><td><strong>Peak penetration (2030E)<\/strong><\/td><td>\u2013<\/td><td>60%<\/td><\/tr><tr><td><strong>China revenue potential<\/strong><\/td><td>\u2013<\/td><td>\u00a5168\u202fmillion (US$23\u202fmillion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Orphan Drug Pathway<\/strong>: SPARK inclusion positions risovalisib for <strong>2026\u20112027 NRDL negotiation<\/strong> under rare disease provisions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Target<\/th><th>Indication<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Risovalisib<\/strong><\/td><td><strong>Haihe Biopharma<\/strong><\/td><td><strong>PI3K\u03b1<\/strong><\/td><td>PROS\/PRVM (pediatric)<\/td><td><strong>SPARK Project<\/strong><\/td><\/tr><tr><td><strong>Alpelisib<\/strong><\/td><td>Novartis<\/td><td>PI3K\u03b1<\/td><td>Breast cancer<\/td><td>Marketed (adult only)<\/td><\/tr><tr><td><strong>Copanlisib<\/strong><\/td><td>Bayer<\/td><td>PI3K\u03b1\/\u03b4<\/td><td>B\u2011cell lymphoma<\/td><td>Marketed (adult only)<\/td><\/tr><tr><td><strong>Taselisib<\/strong><\/td><td>Roche<\/td><td>PI3K\u03b1<\/td><td>Solid tumors<\/td><td>Discontinued<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Advantage<\/strong>: Risovalisib is the <strong>only PI3K\u03b1 inhibitor<\/strong> in development specifically for pediatric PIK3CA\u2011related disorders, with <strong>global IP protection<\/strong> and <strong>regulatory fast\u2011track<\/strong> in China.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding risovalisib\u2019s regulatory pathway, market potential, and partnership dynamics with Taiho Pharmaceutical. Actual results may differ due to clinical trial outcomes, competitive responses, and NMPA pricing decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52240,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[16,1910],"class_list":["post-52239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-cancer","tag-haihe-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haihe Biopharma&#039;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1 inhibitor, has been included in the Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project) by China\u2019s Center for Drug Evaluation (CDE). The designation covers PIK3CA\u2011Related Overgrowth Spectrum (PROS) and PIK3CA\u2011Related Vascular Malformations (PRVM) in pediatric patients requiring systemic therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52239\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haihe Biopharma&#039;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders\" \/>\n<meta property=\"og:description\" content=\"Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1 inhibitor, has been included in the Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project) by China\u2019s Center for Drug Evaluation (CDE). The designation covers PIK3CA\u2011Related Overgrowth Spectrum (PROS) and PIK3CA\u2011Related Vascular Malformations (PRVM) in pediatric patients requiring systemic therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52239\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T05:59:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T05:59:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haihe Biopharma&#8217;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders\",\"datePublished\":\"2025-12-30T05:59:40+00:00\",\"dateModified\":\"2025-12-30T05:59:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3003.webp\",\"keywords\":[\"Cancer\",\"Haihe Biopharma\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52239#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52239\",\"name\":\"Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3003.webp\",\"datePublished\":\"2025-12-30T05:59:40+00:00\",\"dateModified\":\"2025-12-30T05:59:41+00:00\",\"description\":\"Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1 inhibitor, has been included in the Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project) by China\u2019s Center for Drug Evaluation (CDE). The designation covers PIK3CA\u2011Related Overgrowth Spectrum (PROS) and PIK3CA\u2011Related Vascular Malformations (PRVM) in pediatric patients requiring systemic therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52239\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3003.webp\",\"width\":1080,\"height\":608,\"caption\":\"Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52239#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haihe Biopharma&#8217;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders - Insight, China&#039;s Pharmaceutical Industry","description":"Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1 inhibitor, has been included in the Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project) by China\u2019s Center for Drug Evaluation (CDE). The designation covers PIK3CA\u2011Related Overgrowth Spectrum (PROS) and PIK3CA\u2011Related Vascular Malformations (PRVM) in pediatric patients requiring systemic therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52239","og_locale":"en_US","og_type":"article","og_title":"Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders","og_description":"Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1 inhibitor, has been included in the Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project) by China\u2019s Center for Drug Evaluation (CDE). The designation covers PIK3CA\u2011Related Overgrowth Spectrum (PROS) and PIK3CA\u2011Related Vascular Malformations (PRVM) in pediatric patients requiring systemic therapy.","og_url":"https:\/\/flcube.com\/?p=52239","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-30T05:59:40+00:00","article_modified_time":"2025-12-30T05:59:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52239#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52239"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haihe Biopharma&#8217;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders","datePublished":"2025-12-30T05:59:40+00:00","dateModified":"2025-12-30T05:59:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52239"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52239#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp","keywords":["Cancer","Haihe Biopharma"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52239#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52239","url":"https:\/\/flcube.com\/?p=52239","name":"Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52239#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52239#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp","datePublished":"2025-12-30T05:59:40+00:00","dateModified":"2025-12-30T05:59:41+00:00","description":"Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3K\u03b1 inhibitor, has been included in the Pilot Program to Encourage the Development of Pediatric Anti\u2011Tumor Drugs (SPARK Project) by China\u2019s Center for Drug Evaluation (CDE). The designation covers PIK3CA\u2011Related Overgrowth Spectrum (PROS) and PIK3CA\u2011Related Vascular Malformations (PRVM) in pediatric patients requiring systemic therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52239#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52239"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52239#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp","width":1080,"height":608,"caption":"Haihe Biopharma's Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52239#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haihe Biopharma&#8217;s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52239"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52239\/revisions"}],"predecessor-version":[{"id":52241,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52239\/revisions\/52241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52240"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}